Exosomes derived from hypoxia-preconditioned mesenchymal stem cells (hypoMSCs-Exo): advantages in disease treatment

Cell Tissue Res. 2023 Jun;392(3):621-629. doi: 10.1007/s00441-023-03758-6. Epub 2023 Feb 13.

Abstract

Mesenchymal stem cells (MSCs)-based therapy has been reported to be a potential approach to treat various diseases and the paracrine role might be the underlying mechanism. Exosomes were considered an important part of this paracrine role. It was reported that maintenance of MSCs in hypoxia conditions for a short time has shown to be beneficial for the therapeutic effect of MSCs and MSCs-derived exosomes. In this review, we summarized the recent developments on exosomes derived from hypoxia-preconditioned mesenchymal stem cells (hypoMSCs-Exo), including the characteristics of hypoMSCs-Exo in morphology and contents, diseases in which hypoMSCs-Exo showed more effective, and the cellular and molecular mechanisms that hypoMSCs-Exo showed more effective in disease treatment. Besides, we also discussed the limitations of current studies and the issues that needed to be improved in the application of hypoMSCs-Exo. This review aimed to promote a comprehensive and systematic understanding of this type of exosome with great therapeutic potential.

Keywords: Applications; Characteristics; Exosomes; Hypoxia; Mechanisms; Mesenchymal stem cells.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Exosomes*
  • Humans
  • Hypoxia / therapy
  • Mesenchymal Stem Cells*
  • Neovascularization, Physiologic